| Abstract: |
Mature lymphoid neoplasms are simply divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL); the latter is the sixth most common cancer and the ninth leading cause of death. In addition to clinical information, benign findings and pitfalls in fludeoxyglucose (FDG) PET/CT reading, and teaching cases, this chapter reviews evidence-based recommendations regarding PET/CT examination in lymphoma and compares them with statements in major clinical guidelines. There are abundant articles in the literature that discuss the outstanding role of FDG PET/CT in staging, restaging, therapy response assessment, and detection of transformation in HL and NHL. Its ability to predict prognosis in patients with lymphoma is also well addressed in the medical literature. According to evidence-based data, FDG PET/CT is also recommended for the evaluation of posttransplant lymphoproliferative disorders. © 2018 Elsevier Inc. |
